{"entity":{"id":"nct04099251","kind":"trial","name":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","aka":["CheckMate 76K"],"tldr":"A phase 3 trial of Nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma is a phase 3 interventional study registered as NCT04099251 by Bristol-Myers Squibb, with 790 participants enrolled, started 2019-10-28 and due to reach its primary completion in 2022-06-28. Interventions recorded: Nivolumab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04099251","url":"https://clinicaltrials.gov/study/NCT04099251"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","stage-ii-melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-76k-nat-med-2023"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04099251","phase":"3","setting":"A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma","sponsor":"Bristol-Myers Squibb","started":"2019-10-28","startedType":"actual","enrolled":790,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04099251/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"paper":[{"id":"paper-checkmate-76k-nat-med-2023","kind":"paper","name":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","route":"/key-papers/paper-checkmate-76k-nat-med-2023/"}]}}